Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis

Phase 2AC-101Positive

AI Analysis

Summary

Accro Bioscience announced the first patient dosed in a Phase IIb clinical trial of AC-101 for moderate-to-severe ulcerative colitis. The company is advancing AC-101 as a novel therapeutic for immune-mediated diseases.

Clinical Trial Data

Phase

IIb

Importance:5/10

Sentiment:

0.50

Phase IIbUlcerative ColitisClinical DevelopmentFirst Patient Dosed

Related Companies

$BHIC $CHHE $TRAX

Read the original article

Published by PR Newswire Pharma on September 20, 2026 10:00 AM

Read Original